|
Amphotericin B, voriconazole and caspofungin activity against Aspergillus fumigatus in
an in vitro pharmacokinetic/pharmacodynamic (PK/PD) diffusion system simulating
human pharmacokinetics (click for details) |
|
|
|
Characteristics of vulvovaginitis caused by Saccharomyces cerevisiae and antifungal
susceptibility of clinical isolates (click for details) |
|
|
|
Influence of serum on in vitro susceptibility testing of echinocandins for Candida
parapsilosis and Candida guilliermondii (click for details) |
|
|
|
Therapeutic drug monitoring of voriconazole in pediatric patients (click for details) |
|
|
|
Cumulative Diagnostic Value of Galactomannan and Anti-Aspergillus Antibodies
Detection in Children with Haematooncology Diseases (click for details) |
|
|
|
Building work in a paediatric haematology/oncology unit: successful strategies to
prevent invasive fungal infection in immunocompromised patients during construction
of HEPA-filtered cubicles (click for details) |
|
|
|
Susceptible patterns of Candida species isolates from a Portuguese oncology
population - changing strategies? (click for details) |
|
|
|
GI as a portal of entry (click for details) |
|
|
|
Prophylaxis, empirical, preemptive therapy in presumed aspergillosis in
hematolological patients: Which strategy? (click for details) |
|
|
|
EUCAST vs CLSI, Antifungal susceptibility testing (click for details) |
|
|
